A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity-Reference-Cited by-同舟云学术

A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity

Published:2023-08 Issue:8 Volume:41 Page:1498-1515.e10
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Meiser Philippa,Knolle Moritz A.,Hirschberger Anna,de Almeida Gustavo P.,Bayerl Felix,Lacher Sebastian,Pedde Anna-Marie,Flommersfeld Sophie,Hönninger Julian,Stark Leonhard,Stögbauer Fabian,Anton Martina,Wirth Markus,Wohlleber Dirk,Steiger Katja,Buchholz Veit R.,Wollenberg Barbara,Zielinski Christina E.,Braren Rickmer,Rueckert Daniel,Knolle Percy A.,Kaissis Georgios,Böttcher Jan P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference82 articles.

1. The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity;Böttcher;Trends Cancer,2018

2. Dendritic cells in cancer immunology and immunotherapy;Wculek;Nat. Rev. Immunol.,2020

3. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control;Böttcher;Cell,2018

4. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity;Broz;Cancer Cell,2014

5. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity;Hildner;Science,2008

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expansion of tumor-reactive CD8 ⁺ T cell clonotypes occurs in the spleen in response to immune checkpoint blockade;Science Immunology;2024-09-13

2. Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes;Molecular Cancer;2024-09-09

3. N‐Dihydrogalactochitosan Drives Conventional and Alternative Activations of STING to Synergize Type I IFN and IL‐1β Productions for Antitumor Immunity.;Advanced Functional Materials;2024-09-09

4. Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders;Advanced Science;2024-09-09

5. In vivo dendritic cell reprogramming for cancer immunotherapy;Science;2024-09-05